HIV Seropositivity Clinical Trial
Official title:
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
This cross-sectional survey will be conducted prospectively in 2 communes in the Battambang
Province, Roka and Prey Khpos commune. The principal objective of the study is to compare HIV
and HCV prevalence rates in three groups of subjects as follows:
- Group 1: subjects living in Roka and Ambaeng Thngae villages where most of HIV and HCV
cases were identified during the Roka outbreak in 2014-2015
- Group 2: subjects living in the other 4 villages of the Roka commune (Ta Haen I and II,
Pou Batdambang, and Chhung Tradak)
- Group 3: subjects living in selected villages from Prey Khpos commune 1,098 eligible
residents will be selected using three-stage cluster sampling method. A structure
questionnaire will assess the medical injection practices through face-to-face
interview. The study will be conducted into two steps. The first step will be a
prevalence study to assess HIV and HCV prevalence rates in three groups of subject;
Group 1: subjects living in Roka and Ambaeng Thngae villages where most of HIV and HCV
cases were identified during the Roka outbreak; Group 2: subjects living in the other 4
villages of the Roka commune (Ta Haen I and II, Pou Batdambang, and Chhung Tradak) and
Group 3: subjects living in villages from Prey Khpos commune).The second step will be
the phylogenetic study of HIV. The phylogenetic study of HIV will be performed ONLY if
HIV prevalence rates among group 2 and/or group 3 is higher or equal to 0.7% (upper
limit of confidence interval of HIV prevalence estimated in Cambodia)
Objectives
1. General objective
The principal objective of the study is to compare HIV and HCV prevalence rates in three
groups of subjects as follows:
- Group 1: subjects living in Roka and Ambaeng Thngae villages where most of HIV and
HCV cases were identified during the Roka outbreak in 2014-2015
- Group 2: subjects living in the other 4 villages of the Roka commune (Ta Haen I and
II, Pou Batdambang, and Chhung Tradak)
- Group 3: subjects living in selected villages from Prey Khpos commune belonging to
the Battambang Province.
2. Specific objectives
Given the results we obtained during the investigation of the Roka nosocomial outbreak
(2014-15), specific objectives are defined as follows:
- Risk of geographical spread of clustered HCV strains from Roka or Ambaeng Thngae
villages to other villages of the Roka commune
- Risk of geographical spread of clustered HIV strains from Roka or Ambaeng Thngae
villages to other villages of the Roka commune if the HIV prevalence of Group 2 and/or
Group 3 is higher or equal to 0.7% (upper limit of confidence interval of HIV prevalence
estimated in Cambodia).
- Comparison of unsafe injection and/or medical practices between the three groups
Methodology This cross-sectional survey will be conducted prospectively in 2 communes in the
Battambang Province, i.e. the Roka commune and Prey Khpos commune of the Battambang province.
A total of 1,098 eligible residents will be selected according to a three-stage cluster
sampling method conducted in the selected sites. A structure questionnaire will assess the
medical injection practices through a face-to-face interview. The study will be conducted
into two steps. The first step will be a prevalence study to assess HIV and HCV prevalence
rates in three groups of subject; Group 1: subjects living in Roka and Ambaeng Thngae
villages where most of HIV and HCV cases were identified during the Roka outbreak; Group 2:
subjects living in the other 4 villages of the Roka commune (Ta Haen I and II, Pou
Batdambang, and Chhung Tradak) and Group 3: subjects living in villages from Prey Khpos
commune belonging to the Battambang Province.
The second step will be the phylogenetic study of HIV. The phylogenetic study of HIV will be
performed ONLY if HIV prevalence rates among group 2 and/or group 3 is higher or equal to
0.7% (upper limit of confidence interval of HIV prevalence estimated in Cambodia). If the
result of HIV prevalence rates among group 2 and group 3 is lower or equal to 0.6% (HIV
prevalence estimated in Cambodia), the phylogenetic study of HIV will NOT be performed.
A blood test will be done for HIV and HCV serological antibody screening. For the
participants known as HIV positive and/or under ART treatment with NCHADS or as HCV positive,
HCV and/or HIV antibody test will not be repeated for these participants and they will be
considered as HCV and/or HIV positive. All individuals who will test positive for HCV will be
further assessed for viral load measurements. In case of detectable VL results in plasma HCV
strains will be amplified, sequenced, and characterized.
In the second step, all individuals who will test positive for HIV will be further assessed
for viral load measurements. In case of detectable VL results in plasma or by using whole
blood and/or peripheral blood mononuclear cells (PBMCs) in case of undetectable plasma HIV-1
RNA VL results, viral HIV strains will be amplified, sequenced, and characterized.
All tested participants will get a referral slip to retrieve their results (or those from
their child) at health care center in the coverage area. Result disclosure will be provided
by the doctor (or midwife or nurse) in each center. In case of positive result for at least
one virus, we'll advice for the spouse to be tested as well. The same will be suggested for
mothers and/or fathers whose child will be identified as infected. The transportation fee for
this referral will be offered by the survey.
The total duration of this survey is expected to be 12 months.
Estimated enrollment 1,098 participants
Statistical methods
1. Sample size The formula for two-group comparison was used to calculate the sample size,
taking into account the design effect and refusal rate. The minimum sample size of 366
is required per group. Therefore, the total sample size for the 3 groups of subjects in
the 2 communes in Battambang will be 1,098 individuals.
2. Sampling strategies A three-stage cluster sampling method will be used to select the
eligible participants among residents in the 2 communes in Battambang. This sampling
method will be done according to three steps. First, we will select Roka and Prey Khpos
Khpos commune in the Battambang province (a commune that looks alike Roka in terms of
number of inhabitants is selected). Second, the Simple Random sampling will be used to
select 1414 clusters (which are groups) for each group of study population. Third,
simple random sampling strategy will be used to select 26 households from each cluster
(group) and only one person will be selected per household. The next adjacent household
will be used if the person is not present after 3 visits in the first visited household.
If more than one person occupies the visited household, one participant will be randomly
selected for blood test and face-to-face interview with the research team. If the
selected participant is a child, the face-to-face interviews will be done with
parent/legal guardian.
3. Data analysis plan
Data analyses will include:
- Description of the participants' demographic characteristics,
- Comparison of HIV and HCV prevalence rates in 3 different groups (subjects living in
Roka and Ambaeng Thngae villages of Roka commune, individuals living in the other 4
villages of the Roka commune, and people living in other villages of Prey Khpos commune
in the Battambang) using Chi-squared test,
- Comparison of injection history in subjects living in Roka and Ambaeng Thngae villages
of Roka versus residents from other villages using Chi-squared test,
- Comparison of viral strains circulating in Roka and Ambaeng Thngae villages of Roka
commune versus those present in other villages.
Finally, multiple logistic regression models will be used to assess the independence of
variables. All statistical analysis will be performed using STATA version 13.1 software
(StataCorp LP, College Station, USA).
Survey timetable Survey start date: Second semester of 2019 Enrolment period: 2 months
Subject participation duration: Cross-sectional study Total survey duration: 12 months
Estimated survey/trial completion date: Second semester of 2020
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
Completed |
NCT00381212 -
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05983536 -
The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
|
||
Recruiting |
NCT04832477 -
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
|
N/A | |
Completed |
NCT03218839 -
Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males
|
N/A | |
Active, not recruiting |
NCT00797030 -
Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus
|
Phase 4 | |
Recruiting |
NCT04088916 -
Proviral DNA as a Target for HIV-1 Resistance Analysis
|
||
Completed |
NCT03367130 -
Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in Nepal
|
N/A | |
Completed |
NCT04849767 -
National Survey About Trajectory and Life Conditions of HIV Trans People in France
|
||
Completed |
NCT05674682 -
Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study
|
N/A | |
Recruiting |
NCT05174234 -
Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French Guiana
|
||
Completed |
NCT00130819 -
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
|
Phase 2 | |
Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
Recruiting |
NCT03858478 -
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST
|
Phase 4 | |
Completed |
NCT02154971 -
Assessment of Age-related Hearing Loss in HIV-1 Patients
|
||
Recruiting |
NCT03333083 -
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
|
Phase 3 | |
Recruiting |
NCT03311945 -
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
|
Phase 3 | |
Recruiting |
NCT03795415 -
ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in Mali
|
||
Completed |
NCT02003989 -
Revealing Increased Axonal Loss in Treated HIV Patients
|
N/A | |
Completed |
NCT01881971 -
Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center
|
Early Phase 1 |